Startup profile · funding coverage
CAMP4 Therapeutics funding, valuation and investors
Regulatory RNA-targeting therapeutics to upregulate gene expression.
Keep track of CAMP4 Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$100M · 2022
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$130M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
public
public
Investors in latest funding
Other: Andreessen Horowitz
Overview
CAMP4 Therapeutics develops regulatory RNA (regRNA) therapeutics designed to upregulate gene expression for genetic diseases. a16z led a $30M Series A in 2018; a $100M Series B followed in 2022 led by Enavate Sciences. The company went public on Nasdaq (CAMP) in 2025 following private placement activity.
Why CAMP4 Therapeutics is interesting
CAMP4 maps regRNA biology to restore healthy protein levels — a16z led the Series A before the company went public on Nasdaq (CAMP).
Product & use cases
RNA actuators targeting regulatory RNA to restore healthy protein levels in genetic disease — computational biology platform.
- Genetic diseases requiring upregulated gene expression
- RegRNA-targeted small molecule or RNA therapeutics
- Platform expansion across gene targets
Key facts
- Public (Nasdaq: CAMP): private placement and public listing activity in 2025 (CAMP4 IR)
- Series A (2018): $30M led by a16z; Polaris, Kraft Group participated (GenomeWeb)
- Series B (2022): $100M led by Enavate Sciences; a16z re-upped (BusinessWire)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
- Source: https://www.genomeweb.com/business-news/computational-biology-startup-camp4-therapeutics-launches-30m-series-funding
Funding history (newest first)
Investors in our directory
Funds linked from CAMP4 Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: CAMP4 Therapeutics differentiates through focused product scope and a16z-backed GTM in its category — see competitors for tradeoffs vs. incumbents.
CAMP4 Therapeutics operates in a competitive category where incumbents have distribution but startups win on workflow fit. See named competitors for honest better/worse notes; we do not invent market share.
-
Moderna incumbent
RNA therapeutics leader; different mechanism focus.
-
Alnylam adjacent
RNAi downregulation vs. CAMP4 upregulation approach.
Notable stories
- Public (Nasdaq: CAMP): private placement and public listing activity in 2025 (CAMP4 IR)
- Series A (2018): $30M led by a16z; Polaris, Kraft Group participated (GenomeWeb)
Industries
Market / IPO context
Ticker: CAMP (NASDAQ)
IPO status: public
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover CAMP4 Therapeutics's financing or category context.
FAQs about CAMP4 Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.